6.4.3 Lack of Proper Testing and Approval Processes

Recommendations

The testimonies and findings from the NCI Report underscore the need for:

1. Immediately Discontinuing Use of mRNA vaccines.

2. Reverting to Rigorous Approval Standards: The new expedited approval processes should be revoked, and Health Canada should return to its historical safety requirements that ensure comprehensive preclinical and clinical testing before approval.

3. Ensuring Transparency: Regulatory changes should be transparent, involving public consultation and clear communication with stakeholders, including healthcare professionals and the public.

4. Independent Oversight: Establishing an independent body to conduct safety reviews free from industry influence is crucial for maintaining public trust and ensuring patient safety.

5. Strengthening Post-Market Surveillance: Continuous monitoring of approved pharmaceuticals is essential to detect and address any safety concerns that may arise over time.

6. Balancing Innovation and Safety: While promoting innovation is important, it should not compromise patient safety. Long-term effects of novel drugs must be considered, and ethical considerations should be integrated into the approval process.